Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 16/20 | 0.72 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.61 |
| ▸ | RET | P07949 | 1/20 | 0.61 |
| ▸ | KIT | P10721 | 1/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.61 |
| ▸ | FLT1 | P17948 | 1/20 | 0.61 |
| ▸ | FLT4 | P35916 | 1/20 | 0.61 |
| ▸ | KDR | P35968 | 1/20 | 0.61 |
| ▸ | FRK | P42685 | 1/20 | 0.61 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.61 |
| ▸ | LDHA | P00338 | 1/20 | 0.54 |
| ▸ | LDHB | P07195 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | BCR | P11274 | 1/20 | 0.47 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13339854 | 0.93 | CSF1R (0.77) | CSF1RPDGFRBPDGFRARETKIT | |
| SCHEMBL20100907 | 0.92 | CSF1R (0.73) | CSF1RPDGFRBPDGFRARETKIT | |
| SCHEMBL20101078 | 0.89 | CSF1R (0.75) | CSF1RPDGFRBPDGFRARETKIT | |
| SCHEMBL13339898 | 0.89 | CSF1R (0.71) | CSF1RPDGFRBPDGFRARETKIT | |
| SCHEMBL18023928 | 0.88 | CSF1R (0.71) | CSF1RPDGFRBPDGFRARETKIT | |
| SCHEMBL18023930 | 0.88 | CSF1R (0.64) | CSF1RPDGFRBPDGFRARETKIT | |
| SCHEMBL18023929 | 0.88 | CSF1R (0.68) | CSF1RPDGFRBPDGFRARETKIT | |
| SCHEMBL20101087 | 0.88 | CSF1R (0.70) | CSF1RPDGFRBPDGFRARETKIT | |
| SCHEMBL13340112 | 0.88 | CSF1R (0.70) | CSF1RPDGFRBPDGFRARETKIT | |
| SCHEMBL19447186 | 0.88 | CSF1R (0.70) | CSF1RPDGFRBPDGFRARETKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11364238-B2 | Combination therapy for treating pulmonary hypertension | PULMOKINE, INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20210038510-A1 | FORMULATIONS OF KINASE INHIBITORS AND PROSTANOIDS | PULMOKINE, INC. | 2021-02-11 | — | — | US | disclosed |
| WO-2019157337-A1 | FORMULATIONS OF KINASE INHIBITORS AND PROSTANOIDS | PULMOKINE, INC. (US) | 2019-08-15 | — | — | WO | disclosed |
| US-10231966-B2 | Combination therapy for treating pulmonary hypertension | PULMOKINE, INC. (US) | 2019-03-19 | — | — | US | disclosed |
| WO-2018081567-A1 | COMBINATION THERAPY FOR TREATING PULMONARY HYPERTENSION | PULMOKINE, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20180117039-A1 | COMBINATION THERAPY FOR TREATING PULMONARY HYPERTENSION | PULMOKINE, INC. | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10231966-B2 | Combination therapy for treating pulmonary hypertension | EDNRB, EDNRA, PDGFRB | CSF1R 551/4885PDGFRB 3/4885PDGFRA 7/4885 |
| US-20210038510-A1 | FORMULATIONS OF KINASE INHIBITORS AND PROSTANOIDS | PTGIR, PTGIS, PTGFR | CSF1R 1178/4885PDGFRB 5/4885PDGFRA 7/4885 |
| US-20180117039-A1 | COMBINATION THERAPY FOR TREATING PULMONARY HYPERTENSION | EDNRB, EDNRA, PDGFRB | CSF1R 551/4885PDGFRB 3/4885PDGFRA 7/4885 |
| US-11364238-B2 | Combination therapy for treating pulmonary hypertension | EDNRB, EDNRA, PDGFRB | CSF1R 551/4885PDGFRB 3/4885PDGFRA 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.